Close Menu

NEW YORK – OpGen said Thursday that its subsidiary Curetis will have access to an additional €5 million ($5.65 million) debt financing tranche that it plans to use for research and development activities related to the COVID-19 pandemic.

The debt financing facility was originally placed in 2016 and amended in 2019, and the additional €5 million will be used to co-fund R&D programs related to COVID-19 across "several of the platforms and the entire product portfolio" of Curetis and Ares Genetics, another subsidiary of OpGen, the company said in a statement. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.